Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Elizabeth Mittendorf, MD, PhD, discusses the IMpassion-130 clinical trial presented at ESMO 2020

Dr. Mittendorf, Director of the Breast Immuno-Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Rob and Karen Hale Distinguished Chair, discusses the long-term overall survival analysis of the IMpassion-130 clinical trial investigating the atezolizumab and nab paclitaxel combination in triple negative metastatic breast cancer (TNBC) patients presented at the 2020 ESMO Virtual Congress

Tags: BreastESMO

Published: 01 October 2020

Recent Videos: Breast

video

Elizabeth Mittendorf, MD, PhD, discusses the outcomes of the IMpassion-031 study

Dr. Mittendorf, Director of the Breast Immuno-Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Rob and Karen Hale Distinguished Chair, discusses ...

video

Elizabeth Mittendorf, MD, PhD, on the implications of the IMpassion-130 and IMpassion-131 trials

Dr. Mittendorf, Director of the Breast Immuno-Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Rob and Karen Hale Distinguished Chair, on ...

video

Elizabeth Mittendorf, MD, PhD, considers key takeaways from the Impassion-131 presented at ESMO 2020

Dr. Mittendorf, Director of the Breast Immuno-Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Rob and Karen Hale Distinguished Chair, considers ...

video

Elizabeth Mittendorf, MD, PhD, discusses the IMpassion-130 clinical trial presented at ESMO 2020

Dr. Mittendorf, Director of the Breast Immuno-Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Rob and Karen Hale Distinguished Chair, discusses ...

video

Aditya Bardia, MD, MPH, considers the practice-changing potential of the ASCENT study from ESMO 2020

Dr. Bardia, Assistant Professor of Medicine, Harvard Medical School, Attending Physician, Medical Oncology, Massachusetts General Hospital, speculates on whether the ...

video

Aditya Bardia, MD, MPH, describes the outcomes from the Phase III ASCENT study from ESMO 2020

Dr. Bardia, Assistant Professor of Medicine, Harvard Medical School, Attending Physician, Medical Oncology, Massachusetts General Hospital, describes the outcomes from ...

video

Aditya Bardia, MD, MPH, discusses the design of newly approved sacituzumab govitecan

Dr. Bardia, Assistant Professor of Medicine, Harvard Medical School, Attending Physician, Medical Oncology, Massachusetts General Hospital, discusses the design of ...

video

Erika Hamilton, MD, shares thoughts on tolerability in high risk early breast cancer patients

Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, shares thoughts on the tolerability ...

video

Erika Hamilton, MD, considers the comparison between the monarchE and PALLAS clinical trials

Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, considers the comparison between the ...

video

Erika Hamilton, MD, considers the significance of the MonarchE study & the use of abemaciclib

Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, considers the impact of the ...

Related Videos

video-image

Elizabeth Mittendorf, MD, PhD, discusses the outcomes of the IMpassion-031 study

video-image

Elizabeth Mittendorf, MD, PhD, on the implications of the IMpassion-130 and IMpassion-131 trials

video-image

Elizabeth Mittendorf, MD, PhD, considers key takeaways from the Impassion-131 presented at ESMO 2020

video-image

Aditya Bardia, MD, MPH, considers the practice-changing potential of the ASCENT study from ESMO 2020

video-image

Aditya Bardia, MD, MPH, describes the outcomes from the Phase III ASCENT study from ESMO 2020

video-image

Aditya Bardia, MD, MPH, discusses the design of newly approved sacituzumab govitecan

video-image

Erika Hamilton, MD, shares thoughts on tolerability in high risk early breast cancer patients

video-image

Erika Hamilton, MD, considers the comparison between the monarchE and PALLAS clinical trials

video-image

Erika Hamilton, MD, considers the significance of the MonarchE study & the use of abemaciclib

video-image

Erika Hamilton, MD, regarding the Phase III monarchE trial presented at ESMO 2020

video-image

Erika Hamilton, MD, on how CDK4/6 inhibitors transformed the management of metastatic breast cancer

video-image

Erika Hamilton, MD, on the standard of care for high-risk early HR+, HER2- breast cancer

video-image

Sara Hurvitz, MD, describes the recently reported results using PARP inhibition and cisplatin

video-image

Sara Hurvitz, MD, discusses the recently announced results of Monarch E and PALLAS adjuvant trials

video-image

Sara Hurvitz, MD, shares design and outcomes of the HER2CLIMB study in advanced breast cancer

video-image

Debu Tripathy, MD, describes the evolving role of PARP inhibitors in breast cancer patients

video-image

Debu Tripathy, MD, introduces new information onCDK4/6 inhibitors discussed at ASCO20

video-image

Debu Tripathy, MD, on presentations pertaining to immunotherapy in early breast cancer treatment

video-image

Debu Tripathy, MD, discusses recent FDA approvals and HER2+ metastatic breast cancer management

video-image

Nancy Lin, MD, on impressions of the Phase 2 study done the by the Translational Breast Cancer Consortium

video-image

Nancy Lin, MD, explores the role of CDK4/6 inhibitors in metastatic breast cancer management

video-image

Nancy Lin, MD, discusses the standard of care when adjuvant treating HR+, HER2- early breast cancer

video-image

Nancy Lin, MD, provides perspective on the global Phase 3 PALLAS trial regarding early breast cancer

video-image

Nancy Lin, MD, considers whether the results of the HER2CLIMB study will become a new care standard

video-image

Nancy Lin, MD, on the design and outcomes of the HER2CLIMB study regarding metastatic breast cancer

video-image

Karen Lu, MD, illustrates challenges the MAGENTA study brings up associated with genetic counseling

video-image

Karen Lu, MD, provides opinion on whether genetic counseling should be part of the SOP for breast and ovarian cancer risk

video-image

Karen Lu, MD, shares outcomes of the MAGENTA study investigating the role of genetic counseling

video-image

Véronique Diéras, MD, on the optimal setting in which to receive a PARP inhibitor

video-image

Véronique Diéras, MD, on BRCA-positive metastatic breast cancer & PARP inhibitors

video-image

George Sledge, MD, shares the most relevant findings from the MONARCH-2 trial

video-image

Dennis J. Slamon, MD, PhD, on the significance of the phase III MONALEESA-3 trial

video-image

Véronique Diéras, MD, elaborates on the BROCADE 3 study presented at ESMO 2019

video-image

Banu Arun, MD, regarding the optimal setting for PARP inhibitors in breast cancer treatment

video-image

Banu Arun, MD, on PARP inhibitors in BRCA positive metastatic breast cancer

video-image

Banu Arun, MD, regarding veliparib in breast cancer patients with BRCA mutations

video-image

Joyce O’Shaughnessy, MD, elaborates on the MONALEESA-3 trial presented at ESMO 2019

video-image

Joyce O’Shaughnessy, MD, shares relevant findings from the MONARCH-2 trial

video-image

Joyce O’Shaughnessy, MD, on the role of CDK4/6 inhibitors in the management of TNBC

video-image

Joyce O’Shaughnessy, MD, shares results of the Impassion130 trial presented at ESMO 2019

video-image

Joyce O’Shaughnessy, MD, on differentiating CDK4/6 inhibitors

video-image

Sara M. Tolaney, MD, MPH, provides an overview of the results from the SOPHIA trial

video-image

Debu Tripathy, MD, elaborates on the SOPHIA trial in HER+ metastatic breast cancer

video-image

Debu Tripathy, MD, regarding CDK 4/6 inhibitors in the treatment of breast cancer

video-image

Debu Tripathy, MD, elaborates on outcomes from the ImPassion130 trial

video-image

Debu Tripathy, MD, shares the outcomes of the MONALEESA-7 in premenopausal metastatic breast cancer

video-image

Sara M. Tolaney, MD, MPH, on the efficacy & safety of combination eribulin + pembrolizumab

video-image

Debra Patt, MD, MPH, MBA, considers the role of CDK 4/6 inhibitors in advanced breast cancer

video-image

Sara M. Tolaney, MD, MPH, shares outcomes from the ImPassion130 study in TNBC

video-image

Debra Patt, MD, MPH, MBA, regarding the implications of the ImPassion130 trial in TNBC

video-image

Sara M. Tolaney, MD, MPH, shares outcomes from the MONALEESA-7 trial

video-image

Debra Patt, MD, MPH, MBA, on the important implications of the MONALEESA-7 trial

video-image

Neelima Denduluri, MD, elaborates on the SOPHIA trial data in HER+ metastatic breast cancer

video-image

Neelima Denduluri, MD, regarding the EMBRACA trial in HER2- metastatic breast cancer

video-image

Neelima Denduluri, MD, discusses outcomes from the ImPassion130 trial

video-image

Neelima Denduluri, MD, regarding the MONALEESA-7 trial in premenopausal metastatic breast cancer

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, comments on the TAILORx study from ASCO 2018

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, on the outcomes of the PERSEPHONE clinical trial

video-image

Neelima Denduluri, MD, on the outcomes of the SANDPIPER study presented at ASCO 2018

video-image

Neelima Denduluri, MD, looks back on the Short-HER trial from the 2017 ASCO Annual Meeting

video-image

Neelima Denduluri, MD, offers opinion on the PERSEPHONE trial in early HER2+ breast cancer

video-image

Neelima Denduluri, MD, tells us about the recent updates to breast cancer guidelines

video-image

Neelima Denduluri, MD, comments on the role of CDK4/6 inhibitors

video-image

Neelima Denduluri, MD, regarding the implications of the TAILORx study from ASCO 2018

video-image

Neelima Denduluri, MD, speculates on the implications of taselisib data at ASCO 2018

video-image

Neelima Denduluri, MD, on the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Neelima Denduluri, MD, considers whether the results of TAILORx are practice-changing

video-image

Julie Gralow, MD, speculates on taselisib as a standard of care based on the results of SANDPIPER

video-image

Julie Gralow, MD, tells us about the SANDPIPER proof of concept trial presented at ACSO 2018

video-image

Julie Gralow, MD, comments on the practice-changing implications of the TAILORx study

video-image

Julie Gralow, MD, discusses outcomes from the TAILORx study presented at ASCO 2018

video-image

Julie Gralow, MD, regarding the reduction in cardiac events in the PERSEPHONE study

video-image

Julie Gralow, MD, reflects on the PERSEPHONE trial from the 2018 ASCO Annual Meeting

video-image

Julie Gralow, MD, on the implications of the PERSEPHONE trial in early HER2+ breast cancer

video-image

Julie Gralow, MD, speaks to the significance of the MONALEESA-3 study

video-image

Julie Gralow, MD, elaborates on how to differentiate CDK4/6 inhibitors

video-image

Douglas W. Blayney, MD, discusses the biggest takeaway regarding breast cancer here at ASCO 2018

video-image

Douglas W. Blayney, MD, on if the results of the TAILORx study practice changing

video-image

Douglas W. Blayney, MD, discusses the implications of the TAILORx study

video-image

Douglas W. Blayney, MD, discusses the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Douglas W. Blayney, MD, on differentiating CDK4/6 Inhibitors and if they can be used interchangeably

video-image

Sara M. Tolaney, MD, MPH on whether CDK4/6 inhibitors can be used interchangeably

video-image

Sara M. Tolaney, MD, MPH tells us about the outcomes of the MONARCH 2 study

video-image

Sara M. Tolaney, MD, MPH discusses the practice changing outcomes of the TAILORx study

video-image

Sara M. Tolaney, MD, MPH, discusses the fulvestrant + ribociclib arm of the MONALEESA-3 study

video-image

Sara M. Tolaney, MD, MPH, on whether the results of the TAILORx study are “practice changing”

video-image

Debu Tripathy, MD, on immunotherapies being studied for treatment of metastatic breast cancer

video-image

Debu Tripathy, MD, shares his impressions of the MONALEESA-2 study

video-image

Debu Tripathy, MD, regarding the results of the MONARCH-2 study

video-image

Debu Tripathy, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer

video-image

Mohammad Jahanzeb, MD, FACP, on immunotherapy and treatment of metastatic breast cancer

video-image

Mohammad Jahanzeb, MD, FACP, discusses the results of the MONARCH-2 study presented at ASCO

video-image

Mohammad Jahanzeb, MD, FACP, on the impact of the APHINITY study presented at ASCO

video-image

Neelima Denduluri, MD, discusses exciting new approaches to treating breast cancer

video-image

Neelima Denduluri, MD, describes how CDK 4/6 inhibitors impact breast cancer treatment

video-image

Neelima Denduluri, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer

video-image

Neelima Denduluri, MD, discusses the results of the MONARCH-2 study presented at ASCO

video-image

Julie Gralow, MD, shares perspective on the evolving development immunotherapies in breast cancer

video-image

Lee Schwartzberg, MD, interprets the results of the PALOMA-2 study presented at ASCO 2016

video-image

Lee Schwartzberg, MD, on how liquid biopsies can be used for breast cancer treatment strategies

video-image

Julie Gralow, MD, shares her thoughts on the topic of liquid biopsy in breast cancer.

video-image

Julie Gralow, MD, shares her thoughts on new drugs in development for breast cancer.

video-image

Julie Gralow, MD, on the KRISTINE study

video-image

Julie Gralow, MD, discusses the Monarch 1 study

video-image

Julie Gralow, MD, discusses the outcomes of the PALOMA-2 study presented at ASCO 2016

video-image

Jasgit Sachdev, MD, on new drugs for treating patients w/ triple negative breast cancer.

video-image

Jasgit Sachdev, MD, on liquid biopsy as a promising technology for breast cancer treatment

video-image

Jasgit Sachdev, MD, discusses the PALOMA-2 randomized study

video-image

Mohammad Jahanzeb, MD, FACP on the role of CDK inhibitors and their evolving role in breast cancer

video-image

Mohammad Jahanzeb, MD, FACP comments on rising drug costs relative to more effective therapies

video-image

Mohammad Jahanzeb, MD, FACP talks about impact of CDK4/6 inhibition added to letrozole

video-image

Debu Tripathy, MD on the evidence of palbociclib (Ibrance) efficacy in the PALOMA-2 trial

video-image

Debu Tripathy, MD discusses the PALOMA-2 trial outcomes in ER+/HER2- advanced breast cancer

video-image

Debu Tripathy, MD, on the use of hormonal therapy in the PALOMA-2 clinical study

video-image

Debu Tripathy, MD provides update on breast cancer treatment algorithms impacted by PD-L1

video-image

Debu Tripathy, MD explains how liquid biopsy figures into breast cancer treatment

video-image

Debu Tripathy, MD regarding the MONARCH 1 (abemaciclib) study

video-image

Debu Tripathy, MD on the importance of cdk4/6 for future breast cancer treatments

video-image

Lee S. Schwartzberg, MD, FACP on exciting studies for breast cancer investigational agents

video-image

Lee S. Schwartzberg, MD, FACP discussing Paloma 2 study results from ASCO 2016

video-image

Debu Tripathy, MD, provides perspective on the treatment of HER2+ breast cancer patients

video-image

Eleni Efstathiou, MD, PhD, shares thoughts on the TROPHY-U-01 clinical study presented at ESMO 2020

video-image

Eleni Efstathiou, MD, PhD, provides perspective on the IPATential150 study in mCRPC

video-image

Eleni Efstathiou, MD, PhD, on whether genetic mutation data impacts the treatment of prostate cancer

video-image

Eleni Efstathiou, MD, PhD, on the practice-changing potential of the PROfound study from ESMO 2020

video-image

Eleni Efstathiou, MD, PhD, regarding patients more likely to respond to nivolumab + cabozantinib

video-image

Eleni Efstathiou, MD, PhD, offers opinion on whether CheckMate 9ER is practice-changing

video-image

Eleni Efstathiou, MD, PhD, discusses the CheckMate 9ER clinical trial presented at ESMO 2020

video-image

Matthew Galsky, MD, on how studies focused on genetic mutations impact prostate cancer treatment

video-image

Arun Azad, MBBS, PhD, FRACP, on the evolving treatment landscape of advanced prostate cancer

video-image

Matthew Galsky, MD, discusses the practice-changing potential of the PROfound study from ESMO 2020

video-image

Ken Kato, MD, PhD, on the role of PD-L1 biomarkers in the treatment of esophageal cancer

video-image

Arun Azad, MBBS, PhD, FRACP, considers how recent clinical trials influence the treatment of mCRPC

video-image

Matthew Galsky, MD, considers the implications of the IMvigor130 clinical study

video-image

Arun Azad, MBBS, PhD, FRACP, tells us about the outcomes of the PROfound study presented at ESMO '20

video-image

Matthew Galsky, MD, on the CheckMate-274 study in high risk, muscle-invasive urothelial carcinoma

video-image

Ken Kato, MD, PhD, regarding the treatment of adenocarcinoma versus squamous cell carcinoma

video-image

Arun Azad, MBBS, PhD, FRACP, shares impressions of the post-hoc analysis of the ARCHES study

video-image

Matthew Galsky, MD, regarding the TROPHY-U-01 study presented at the 2020 ESMO Virtual Congress

video-image

Ken Kato, MD, PhD, shares the design and outcomes of the Keynote-590 trial from ESMO 2020

video-image

Ana Maria Arance Fernandez, MD, PhD, on the combination of TKIs and checkpoint inhibitors

video-image

Ana Maria Arance Fernandez, MD, PhD, regrading the LEAP-004 clinical trial presented at ESMO 2020

video-image

Robert L. Coleman, MD, FACOG, FACS, regarding the antibody-drug conjugate tisotumab vedotin

video-image

Ana Maria Arance Fernandez, MD, PhD, on the progress & data in melanoma coming out of ESMO 2020

video-image

Geoffrey Y. Ku, MD, elaborates on the promising PRS-343 compound

video-image

Robert L. Coleman, MD, FACOG, FACS, shares results of the innovaTV 204 study in cervical cancer

video-image

Roy S. Herbst, MD, PhD, shares thoughts on the update to Keynote-024 presented at ESMO 2020

video-image

David S. Hong, MD, regarding the Phase I clinical trial investigating sotorasib (AMG 510)

video-image

Nicholas James, MD, PhD, offers a summary of the STAMPEDE study to date

video-image

Geoffrey Y. Ku, MD, discusses results of the Phase I study investigating PRS-343 in GI malignancies

video-image

Jaffer Ajani, MD, elaborates on the role of PD-L1 biomarkers in determining treatment decisions

video-image

Robert L. Coleman, MD, FACOG, FACS, on next steps in the clinical development of tisotumab vedotin

video-image

Roy S. Herbst, MD, PhD, elaborates on the design and outcomes of the EMPOWER-lung 1 clinical study

video-image

David S. Hong, MD, speculates on the next steps in the development of sotorasib (AMG 510)

video-image

Nicholas James, MD, PhD, analyzes the duration of response in Arm G of the STAMPEDE clinical trial

video-image

Geoffrey Y. Ku, MD, provides perspective on the CheckMate-577 clinical study presented at ESMO 2020

video-image

Robert L. Coleman, MD, FACOG, FACS, shares his impressions of the SOLO-1 update from ESMO 2020

video-image

Roy S. Herbst, MD, PhD, tell us about the PIONeeR study presented at the 2020 ESMO Virtual Congress

video-image

Geoffrey Y. Ku, MD, offers opinion on the practice-changing potential of the CheckMate-649 study

video-image

Robert L. Coleman, MD, FACOG, FACS, on the role of HRD in the management of ovarian cancer

video-image

Roy S. Herbst, MD, PhD, offers his impressions of the ADAURA trial presented at ESMO 2020

video-image

Geoffrey Y. Ku, MD, on treating squamous cell carcinoma versus adenocarcinoma of the esophagus

video-image

Robert L. Coleman, MD, FACOG, FACS, tells us about the negative outcomes from the IMagyn050 study

video-image

Alex Spira, MD, PhD, FACP, on the practice-changing potential of the ADAURA study from ESMO 2020

video-image

Alex Spira, MD, PhD, FACP, offers thoughts on the four-year follow-up to the Phase III PACIFIC trial

video-image

Alex Spira, MD, PhD, FACP, shares thoughts on the Phase I CHRYSALIS study presented at ESMO 2020

video-image

Alex Spira, MD, PhD, FACP, discusses the mechanism of action of amivantamab (JNJ-6372)

video-image

Petros Grivas, MD, PhD, offers perspective on the JAVELIN Bladder 100 trial updated at ESMO 2020

video-image

Petros Grivas, MD, PhD, summarizes the clinical progress made in prostate cancer from ESMO 2020

video-image

Alexander Stratigos, MD, PhD, speculates on next steps in the development of cemiplimab in BCC

video-image

Laurence Albigès, MD, PhD, on patient responses to combo nivolumab + ipilimumab in 1st line RCC

video-image

Jaffer Ajani, MD, considers results from the CheckMate 649 study presented at ESMO 2020

video-image

Laurence Albigès, MD, PhD, regarding the potential challenges when combining checkpoint inhibitors

video-image

Petros Grivas, MD, PhD, discusses the COVID-19 and Cancer Consortium (CCC19) from ESMO 2020

video-image

Alexander Stratigos, MD, PhD, on the latest data investigating the use of cemiplimab in BCC

video-image

Jaffer Ajani, MD, shares thoughts on the CheckMate 577 study presented at ESMO 2020

video-image

Laurence Albigès, MD, PhD, offers opinion on whether CheckMate 214 is practice-changing

video-image

Petros Grivas, MD, PhD, on whether the results of TROPHY-U-01 justify a larger Phase III study

video-image

Zarnie Lwin, MBBS, FRACP, speculates on future development of combo pembrolizumab + lenvatinib

video-image

Alexander Stratigos, MD, PhD, considers the effectiveness of hedgehog inhibitors in BCC

video-image

Jaffer Ajani, MD, provides opinion on the role of I-O in treatment of esophageal & gastric cancers

video-image

Laurence Albigès, MD, PhD, shares outcomes & updates from the CheckMate 214 study in advanced RCC

video-image

Petros Grivas, MD, PhD, offers thoughts on the TROPHY-U-01 clinical study from ESMO 2020

video-image

Zarnie Lwin, MBBS, FRACP, shares the design & outcomes of the LEAP-005 Phase II study from ESMO 2020

video-image

Alexander Stratigos, MD, PhD, provides perspective on the PD-1 biomarker in BCC

video-image

Zarnie Lwin, MBBS, FRACP, on the safety and efficacy of combining TKIs with checkpoint inhibitors

video-image

Andrew Schmidt, MD, speculates on next steps for the COVID-19 and Cancer Outcomes study (CCOS)

video-image

Cristina Suárez, MD, on what physicians should consider when combining checkpoint inhibitors & TKIs

video-image

Andrew Schmidt, MD, regarding the predicted surge in the number of cancer patients due to COVID-19

video-image

Cristina Suárez, MD, on patient subtype responses to combo nivolumab + cabozantinib in 1st line RCC

video-image

Cristina Suárez, MD, offers opinion on whether the CheckMate 9ER trial is practice-changing

video-image

Andrew Schmidt, MD, on interventions that may help correct the disparity in cancer care disruptions

video-image

Cristina Suárez, MD, compares the control arm of CheckMate 9ER with current 1st line RCC regimens

video-image

Andrew Schmidt, MD, on the nature of COVID-19 cancer care disruptions among minority populations

video-image

Cristina Suárez, MD, elaborates on the outcomes of the CheckMate 9ER study presented at ESMO 2020

video-image

Andrew Schmidt, MD, regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented at ESMO 2020

video-image

Cristina Suárez, MD, on the promise of I-O in advanced renal cell carcinoma

video-image

Giuseppe Giaccone, PhD, MD, speculates on next steps in the development of Tedopi (OSE2101)

video-image

Maha Hussain, MD, provides perspective on the Phase III PROfound study presented at ESMO 2020

video-image

Giuseppe Giaccone, PhD, MD, regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCLC

video-image

Pasi A. Jänne, MD, PhD, offers opinion on the next steps in the development of mobocertinib

video-image

Maha Hussain, MD, shares the design of the Phase III PROfound study in mCRPC

video-image

Giuseppe Giaccone, PhD, MD, regarding the mechanism of action of Tedopi (OSE2101)

video-image

Pasi A. Jänne, MD, PhD, shares data from ESMO 2020 investigating mobocertinib

video-image

Maha Hussain, MD, considers the role of homologous recombination repair in the management of mCRPC

video-image

Giuseppe Giaccone, PhD, MD, comments on the incidence of HLA-A2 positive (NSCLC)

video-image

Pasi Jänne, MD, PhD, elaborates on EGFR exon 20 insertions in non-small cell lung cancer

video-image

Maha Hussain, MD, regarding the evolving treatment landscape of mCRPC

video-image

Shirish M. Gadgeel MBBS, comments on significant studies in ALK+ NSCLC from ESMO 2019

video-image

Robert L. Coleman, MD, FACOG, FACS, on takeaways from the ovarian plenary session at ESMO '19

video-image

Amer Zeidan, MBBS, comments on the influx of investigational oral agents in myeloid malignancies

video-image

Arndt Vogel, MD, elaborates on some of the key takeaways from the GO30140 trial

video-image

George Sledge, MD, explains how MONARCH-2 may impact the current standard of care

video-image

Dennis J. Slamon, MD, PhD, discusses implications from the MONALEESA-3 trial

video-image

Nader Sanai, MD, offers perspective on the challenges in treating glioblastoma

video-image

Christian Rolfo, MD, PhD, MBA, on the role of liquid biopsy in the treatment of lung cancer

video-image

Ulrik Lassen, MD, PhD, on whether testing for TRK fusion is easy and reliable

video-image

Scott Kopetz, MD, explains how BRAF mutations figure into treatment algorithms for CRC

video-image

Stefan Kasper, MD, provides updates on the BEACON trial in BRAF-mutant CRC

video-image

Shirish M. Gadgeel MBBS, speculates on the future of RET-altered NSCLC

video-image

Robert L. Coleman, MD, FACOG, FACS, on the VELIA, PAOLA-1 and PRIMA studies

video-image

Amer Zeidan, MBBS, on his study investigating onvansertib + cytarabine or decitabine in AML

video-image

Arndt Vogel, MD, elaborates on the results of the CheckMate-459 study in HCC

video-image

Brian Van Tine, MD, shares some of the top studies in sarcoma presented at ESMO 2019

video-image

Deborah Shrag, MD, MPH, on which biomarkers are important in the diagnosis & management of CRC

video-image

Nader Sanai, MD, shares details from the most promising studies in glioma presented at ESMO 2019

video-image

Christian Rolfo, MD, PhD, MBA, on the development of RET-Fusion in NSCLC

video-image

Ulrik Lassen, MD, PhD, discusses the incidence of TRK fusion in various tumor types

video-image

Scott Kopetz, MD, shares updates from the BEACON trial in BRAF-mutant colorectal cancer

video-image

Stefan Kasper, MD, explains the dosing and administration schedule of cetuximab

video-image

Shirish M. Gadgeel MBBS, regarding the most exciting data in lung cancer from ESMO 2019

video-image

Robert L. Coleman, MD, FACOG, FACS, on how veliparib factors into ovarian cancer treatment

video-image

Brian Van Tine, MD, considers the role of real-world outcomes in the treatment of sarcoma

video-image

Arndt Vogel, MD, offers his opinion on pemigatinib in the management of cholangiocarcinoma

video-image

Jason J. Luke, MD, FACP, on the role of CAR-Ts in the treatment of solid tumors

video-image

David Gershenson, MD, on considerations for maintenance therapy in ovarian cancer

video-image

David Gershenson, MD, tells us what's new in the treatment of rare epithelial cancers

video-image

David Gershenson, MD, elaborates on the role of MEK inhibitor trametinib in LGSC

video-image

Arndt Vogel, MD, shares his impression of the FIGHT-202 trial in cholangiocarcinoma

video-image

Ahmed Kaseb, MD, considers the effectiveness of bevacizumab + atezolizumab in HCC

video-image

Brian Van Tine, MD, discusses the design of the SPEARHEAD-1 trial

video-image

Jason J. Luke, MD, FACP, on the most compelling data in metastatic melanoma from ESMO 2019

video-image

Ahmed Kaseb, MD, elaborates on the phase 1b study investigating atezolizumab + bevacizumab in HCC

video-image

Christopher J. Hoimes, MD, considers the role of I-O in perioperative muscle-invasive bladder cancer

video-image

Brian Van Tine, MD, on the most promising investigational agents in advanced sarcoma

video-image

Jason J. Luke, MD, FACP, on how data from ESMO 2019 may impact the treatment of melanoma

video-image

Ahmed Kaseb, MD, offers opinion on nivolumab + ipilimumab in resectable HCC

video-image

Christopher J. Hoimes, MD, comments on the design and outcomes of KEYNOTE-866

video-image

Christopher J. Hoimes, MD, regarding the EV-103 study presented at ESMO 2019

video-image

Geoffrey Oxnard, MD, on the effectiveness of lorlatinib as a frontline agent in ALK+ NSCLC

video-image

Geoffrey Oxnard, MD, explains how genomic markers can guide treatment in PD-L1 positive NSCLC

video-image

Suresh Ramalingam, MD, provides perspective on the PD-L1 and TMB biomarkers in lung cancer

video-image

David Spigel, MD, on how results from the FLAURA study impact treatment selection in lung cancer

video-image

Suresh Ramalingam, MD, offers opinion on optimal sequencing of immunotherapy in NSCLC

video-image

Michael J. Birrer, MD, PhD, considers the benefits of various PARP inhibitors in ovarian cancer

video-image

David Spigel, MD, tells us about the results of CheckMate-227 presented at ESMO 2019

video-image

Suresh Ramalingam, MD, on how the FLAURA trial may impact care for EGFR-mutated NSCLC

video-image

Marwan Fakih, MD, considers implications from the AMG 510 trial

video-image

Michael J. Birrer, MD, PhD, regarding BRCA status in newly diagnosed ovarian cancer

video-image

Michael J. Birrer, MD, PhD, on the role of maintenance therapy in newly diagnosed ovarian cancer

video-image

Michael J. Birrer, MD, PhD, elaborates on the outcomes from the FORWARD I study

video-image

Michael Birrer, MD, on the key takeaways from the ovarian plenary session in ovarian cancer at ESMO 2019

video-image

David Spigel, MD, on the use of genomic markers like TMB to guide 1st NSCLC treatment

video-image

Geoffrey Oxnard, MD, on the FLAURA study impacting treatment selection in EGFR mutant lung cancer

video-image

Marwan Fakih, MD, on whether MSI-high is a “must-have” biomarker for CRC patients

video-image

Suresh Ramalingam, MD, discusses the results of CheckMate 227 in advanced NSCLC patients

video-image

Nader Sanai, MD, on the role of ribociclib in the management of gliomas

video-image

Suresh Ramalingam, MD, FASCO, shares results from the FLAURA trial presented at ESMO 2019

video-image

Marwan Fakih, MD, discusses the Phase 1 trial evaluating AMG 510 in CRC and NSCLC